No­van shares shoot up on pos­i­tive PhII an­ti-fun­gal gel boast; Apex­i­gen strikes a check­point com­bo agree­ment with Bris­tol-My­ers

→ Shares of Mor­risville, NC-based No­van Ther­a­peu­tics shot up 35% this morn­ing af­ter the biotech re­port­ed that in­ves­ti­ga­tors reaped pos­i­tive top line da­ta from a Phase II tri­al of SB208, their an­ti-fun­gal gel in de­vel­op­ment for in­fec­tions caused by der­mato­phytes such as Tri­chophy­ton rubrum, or T. rubrum. “The re­sults from this Phase 2 tri­al with SB208 con­firm the fungi­ci­dal ac­tiv­i­ty of ni­tric ox­ide ob­served in our pre­clin­i­cal stud­ies,” said Nathan Stasko, Pres­i­dent and Chief Ex­ec­u­tive Of­fi­cer of No­van. “We have now seen clin­i­cal ev­i­dence of an­tibac­te­r­i­al, an­tivi­ral and an­ti­fun­gal ac­tiv­i­ty with prod­uct can­di­dates from our ni­tric ox­ide plat­form. Our abil­i­ty to de­ploy an­timi­cro­bial dos­es of ni­tric ox­ide in this tri­al gives us con­fi­dence to move for­ward in the de­vel­op­ment of a po­ten­tial treat­ment for hard-to-treat in­fec­tions like ony­chomy­co­sis.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.